Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
Pharmacol Res
; 158: 104920, 2020 08.
Article
em En
| MEDLINE
| ID: mdl-32461187
Palavras-chave
Anaplastic thyroid cancer; Lenvatinib; Lenvatinib - IUPAC name: 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide - PubChem CID: 9823820; Sorafenib; Synergism; Vinorelbine; Vinorelbine - IUPAC namemethyl (1R, 9R, 10S, 11R, 12R, 19R)-11-acetyloxy-12-ethyl-4-[(12S, 14R,)-16-ethyl-12-methoxycarbonyl-1, 10-diazatetracyclo[12.3.1.0, (3), (11).0, (4), (9),]octadeca-3(11), 4, 6, 8, 15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8, 16-diazapentacyclo[10.6.1.0, (1), (9).0, (2), (7).0, (16), (19),]nonadeca-2, 4, 6, 13-tetraene-10-carboxylate- PubChem CID 5311497
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Compostos de Fenilureia
/
Quinolinas
/
Neoplasias da Glândula Tireoide
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carcinoma Anaplásico da Tireoide
/
Vinorelbina
Limite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Pharmacol Res
Assunto da revista:
FARMACOLOGIA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Itália